阿瑞匹坦联合托烷司琼预防顺铂化疗后呕吐的效果分析

Analysis of the Effect of Aprepitant Combing Tropisetron on Prevention of Vomiting after Cisplatin Chemtherapy

目的:探讨阿瑞匹坦联合托烷司琼预防顺铂化疗后呕吐的临床效果,总结其临床应用价值。方法:选取2014年06月01日-2014年11月01日我院收治的恶性肿瘤患者60例,均应用含顺铂的化疗方案。按随机数字表法将60例患者分成实验组30例,对照组30例,化疗过程中对照组预防性应用托烷司琼,实验组预防性应用阿瑞匹坦、托烷司琼,比较两组呕吐预防效果。结果:与对照组相比,实验组恶性肿瘤患者的呕吐预防效果更佳。实验组患者急性期、延迟期、全期呕吐完全缓解率分别为86.7%、70.0%、66.7%,与对照组的73.3%、43.3%、40.0%比较,差异有统计学意义(P<0.05)。两组口干、头晕、头痛等不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿瑞匹坦联合托烷司琼治疗恶性肿瘤,可安全、有效地预防呕吐反应,具有一定的临床应用价值。

Objective To investigate the clinical effect of aprepitant combing tropisetron on prevention of vomiting after cisplatin chemtherapy. Methods Sixty patients with malignant applied cisplatin-containing chemotherapy regimens in our hospital from June 1, 2014 to November 1, 2014 were selected and divided into experimental group（30 patients） and control group（30 patients）. The control group were given tropisetron during chemotherapy, while the experimental group were given aprepitant and tropisetron. The two group＇s vomiting preventive effect was compared. Results The experimental group＇ vomiting preventive effect was better than the control group. The complete remission rates of vomiting in control group for acute period, delay period and the whole period were 86.7%, 70.0% and 66.7% respectively, and the difference was statistically signifi cant（P〈0.05） by comparing with experimental group＇s 73.3%, 43.3% and 40.0%. There was not obviously statistically significant（P〉0.05） for dry mouth, dizziness, headaches and other adverse reaction rates. Conclusion Aprepitant combining tropisetron treating to malignant tumors can be safely and effectively to prevent vomiting.